Bone: Incretin Hormones Perceiver or Receiver?

Overview

Journal Exp Diabetes Res

Specialty Endocrinology

Date 2012 Jul 5

PMID 22761607

Citations 14

Authors

Ilaria Dicembrini

Edoardo Mannucci

Carlo Maria Rotella

Affiliations

Soon will be listed here.

Abstract

Novel incretin-based drugs, such as glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i), have been last introduced in the pharmacological treatment of type 2 diabetes. In the last few years, the interest on the relationship of gut hormones with bone metabolism in diabetes has been increasing. The aim of present paper is to examine in vitro and in vivo evidence on the connections between incretin hormones and bone metabolism. We also discuss results of clinical trials and metaanalysis, explore the effects of incretin drugs in vitro on osteogenic cells and osteoclasts, and speculate on the possibility of different effects of GLP-1 RA and DPP-4i on the risk of bone fractures risk in humans. Although existing preliminary evidence suggests a protective effect on the bone, at least for DPP-4i, further controlled, long-term studies with measurement of bone markers, bone density, and clinical fractures rates are needed to substantiate and confirm those findings.

Citing Articles

Bone Loss in Diabetes Mellitus: Diaporosis.

Kupai K, Kang H, Posa A, Csonka A, Varkonyi T, Valkusz Z Int J Mol Sci. 2024; 25(13).

PMID: 39000376 PMC: 11242219. DOI: 10.3390/ijms25137269.

Bone resorption and incretin hormones following glucose ingestion in healthy emerging adults.

Lei W, Rodrick E, Belcher S, Kelly A, Kindler J J Clin Transl Endocrinol. 2023; 31:100314.

PMID: 36845829 PMC: 9950953. DOI: 10.1016/j.jcte.2023.100314.

Bone metabolism and incretin hormones following glucose ingestion in young adults with pancreatic insufficient cystic fibrosis.

Lei W, Kilberg M, Zemel B, Rubenstein R, Harris C, Sheikh S J Clin Transl Endocrinol. 2022; 30:100304.

PMID: 36110921 PMC: 9467887. DOI: 10.1016/j.jcte.2022.100304.

Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women.

Montes Castillo M, Martinez Ramirez M, Soriano Arroyo R, Prieto Gomez I, Segarra Robles A, Garrido-Martinez M Sci Rep. 2019; 9(1):13651.

PMID: 31541189 PMC: 6754449. DOI: 10.1038/s41598-019-50117-z.

Epithelial Barrier Function in Gut-Bone Signaling.

Rios-Arce N, Collins F, Schepper J, Steury M, Raehtz S, Mallin H Adv Exp Med Biol. 2017; 1033:151-183.

PMID: 29101655 PMC: 5742533. DOI: 10.1007/978-3-319-66653-2_8.

References

Bonds D, Larson J, Schwartz A, Strotmeyer E, Robbins J, Rodriguez B . Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab. 2006; 91(9):3404-10. DOI: 10.1210/jc.2006-0614. View

Nuche-Berenguer B, Moreno P, Portal-Nunez S, Dapia S, Esbrit P, Villanueva-Penacarrillo M . Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept. 2009; 159(1-3):61-6. DOI: 10.1016/j.regpep.2009.06.010. View

Walsh J, Henriksen D . Feeding and bone. Arch Biochem Biophys. 2010; 503(1):11-9. DOI: 10.1016/j.abb.2010.06.020. View

Bjarnason N, Henriksen E, Alexandersen P, Christgau S, Henriksen D, Christiansen C . Mechanism of circadian variation in bone resorption. Bone. 2002; 30(1):307-13. DOI: 10.1016/s8756-3282(01)00662-7. View

Mathieu C, Van Der Schueren B . Vitamin D deficiency is not good for you. Diabetes Care. 2011; 34(5):1245-6. PMC: 3114513. DOI: 10.2337/dc11-0307. View

Bardini G, Dicembrini I, Serio M, Rotella C . Vitamin D therapy in adults with diabetes mellitus. Nat Rev Endocrinol. 2011; 7(1):c1. DOI: 10.1038/nrendo.2010.107-c1. View

Chung M, Balk E, Brendel M, Ip S, Lau J, Lee J . Vitamin D and calcium: a systematic review of health outcomes. Evid Rep Technol Assess (Full Rep). 2010; (183):1-420. PMC: 4781105. View

Clowes J, Khosla S, Eastell R . Potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res. 2005; 20(9):1497-506. DOI: 10.1359/JBMR.050524. View

Bunck M, Poelma M, Eekhoff E, Schweizer A, Heine R, Nijpels G . Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. J Diabetes. 2011; 4(2):181-5. DOI: 10.1111/j.1753-0407.2011.00168.x. View

10.

Monami M, Cresci B, Colombini A, Pala L, Balzi D, Gori F . Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care. 2007; 31(2):199-203. DOI: 10.2337/dc07-1736. View

11.

Dicembrini I, Pala L, Rotella C . From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. Exp Diabetes Res. 2011; 2011:898913. PMC: 3124298. DOI: 10.1155/2011/898913. View

12.

Pacheco-Pantoja E, Ranganath L, Gallagher J, Wilson P, Fraser W . Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol. 2011; 11:12. PMC: 3162581. DOI: 10.1186/1472-6793-11-12. View

13.

Ding K, Shi X, Zhong Q, Kang B, Xie D, Bollag W . Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. J Bone Miner Res. 2007; 23(4):536-43. PMC: 2669161. DOI: 10.1359/jbmr.071202. View

14.

Janghorbani M, van Dam R, Willett W, Hu F . Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007; 166(5):495-505. DOI: 10.1093/aje/kwm106. View

15.

Gottschalck I, Jeppesen P, Hartmann B, Holst J, Henriksen D . Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Scand J Gastroenterol. 2008; 43(11):1304-10. DOI: 10.1080/00365520802200028. View

16.

Henriksen D, Alexandersen P, Hartmann B, Adrian C, Byrjalsen I, Bone H . Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone. 2009; 45(5):833-42. DOI: 10.1016/j.bone.2009.07.008. View

17.

Takiishi T, Gysemans C, Bouillon R, Mathieu C . Vitamin D and diabetes. Endocrinol Metab Clin North Am. 2010; 39(2):419-46, table of contents. DOI: 10.1016/j.ecl.2010.02.013. View

18.

Sanz C, Vazquez P, Blazquez C, Barrio P, Alvarez M, Blazquez E . Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. Am J Physiol Endocrinol Metab. 2009; 298(3):E634-43. DOI: 10.1152/ajpendo.00460.2009. View

19.

Nuche-Berenguer B, Portal-Nunez S, Moreno P, Gonzalez N, Acitores A, Lopez-Herradon A . Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol. 2010; 225(2):585-92. DOI: 10.1002/jcp.22243. View

20.

Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E . Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus. Diabet Med. 2000; 17(10):713-9. DOI: 10.1046/j.1464-5491.2000.00367.x. View